Delta9-tetrahydrocannabinol releases and facilitates the effects of endogenous enkephalins: reduction in morphine withdrawal syndrome without change in rewarding effect.
Recent studies have suggested that cannabinoids might initiate the consumption of other highly addictive substances, such as opiates. In this work, we show that acute administration of Delta9-tetrahydrocannabinol in mice facilitates the antinociceptive and antidepressant-like responses elicited by the endogenous enkephalins protected from their degradation by RB 101, a complete inhibitor of enkephalin catabolism. This emphasizes the existence of a physiological interaction between endogenous opioid and cannabinoid systems. Accordingly, Delta9-tetrahydrocannabinol increased the release of Met-enkephalin-like material in the nucleus accumbens of awake and freely moving rats measured by microdialysis. In addition, this cannabinoid agonist displaced the in vivo [3H]diprenorphine binding to opioid receptors in total mouse brain. The repetitive pretreatment during 3 weeks of Delta9-tetrahydrocannabinol in mice treated chronically with morphine significantly reduces the naloxone-induced withdrawal syndrome. However, this repetitive administration of Delta9-tetrahydrocannabinol did not modify or even decrease the rewarding responses produced by morphine in the place preference paradigm. Taken together, these behavioural and biochemical results demonstrate the existence of a direct link between endogenous opioid and cannabinoid systems. However, chronic use of high doses of cannabinoids does not seem to potentiate the psychic dependence to opioids.
Valverde
O
O
Département de Pharmacochimie Moléculaire et Structurale, U266 INSERM, UMR 8600 CNRS, UFR des Sciences Pharmaceutiques et Biologiques, 4, Avenue de l'Observatoire, 75270 Paris Cedex 06, France.
Noble
F
F
Beslot
F
F
Daugé
V
V
Fournié-Zaluski
M C
MC
Roques
B P
BP
D000700:Analgesics / Q000494:pharmacology; D000818:Animals; D001667:Binding, Competitive / Q000187:drug effects / Q000502:physiology; D003213:Conditioning, Psychological / Q000187:drug effects / Q000502:physiology; D004174:Diprenorphine / Q000493:pharmacokinetics; D004220:Disulfides / Q000494:pharmacology; D013759:Dronabinol / Q000494:pharmacology*; D004347:Drug Interactions / Q000502:physiology*; D004744:Enkephalin, Methionine / Q000187:drug effects* / Q000378:metabolism; D005110:Extracellular Space / Q000187:drug effects / Q000378:metabolism; D008297:Male; D051379:Mice; D009020:Morphine / Q000494:pharmacology*; D009043:Motor Activity / Q000187:drug effects / Q000502:physiology; D009292:Narcotic Antagonists / Q000493:pharmacokinetics; D009294:Narcotics / Q000494:pharmacology*; D009474:Neurons / Q000187:drug effects / Q000378:metabolism; D009619:Nociceptors / Q000187:drug effects / Q000378:metabolism; D009714:Nucleus Accumbens / Q000187:drug effects / Q000378:metabolism; D010649:Phenylalanine / Q000031:analogs & derivatives* / Q000494:pharmacology; D011619:Psychotropic Drugs / Q000494:pharmacology*; D012201:Reward; D013375:Substance Withdrawal Syndrome / Q000378:metabolism* / Q000503:physiopathology; D014316:Tritium / Q000493:pharmacokinetics
D000700:Analgesics; D004220:Disulfides; D009292:Narcotic Antagonists; D009294:Narcotics; D011619:Psychotropic Drugs; D014316:Tritium; C074024:RB 101; D004174:Diprenorphine; D010649:Phenylalanine; D004744:Enkephalin, Methionine; D009020:Morphine; D013759:Dronabinol